💊 Medicamentos A-Z 🧬 Alvos 🛠 Ferramentas 📚 Guias
Todos os Medicamentos Classes de Medicamentos Áreas Terapêuticas Efeitos Colaterais
Guias Glossário Linha do Tempo
Comparações Percursos de Medicamentos Famílias de Medicamentos
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Turoctocog Alfa Pegol

CHEMBL5315071 Phase 4 Aprovado Protein
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
— g/mol
LogP
—
Phase
4

Turoctocog alfa pegol (N8-GP) is a PEGylated recombinant factor VIII product where glycoPEGylation extends the half-life of the molecule compared to standard recombinant factor VIII, enabling less frequent dosing for hemophilia A prophylaxis. The glycoPEGylation via O-glycan attachment reduces renal clearance and extends circulatory half-life to approximately 19 hours. It allows once-weekly or less frequent prophylactic dosing while maintaining hemostatic efficacy.

Mecanismo de Ação

As a recombinant protein, it replicates the function of the naturally occurring human protein, supplementing or replacing deficient endogenous production to restore normal physiological activity.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mecanismo

As a recombinant protein, it replicates the function of the naturally occurring human protein, supplementing or replacing deficient endogenous production to restore normal physiological activity.

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Perguntas frequentes

Turoctocog alfa pegol (N8-GP) is a PEGylated recombinant factor VIII product where glycoPEGylation extends the half-life of the molecule compared to standard recombinant factor VIII, enabling less frequent dosing for hemophilia A prophylaxis. The glycoPEGylation via O-glycan attachment reduces renal clearance and extends circulatory half-life to approximately 19 hours. It allows once-weekly or less frequent prophylactic dosing while maintaining hemostatic efficacy.

As a recombinant protein, it replicates the function of the naturally occurring human protein, supplementing or replacing deficient endogenous production to restore normal physiological activity.

Yes, Turoctocog Alfa Pegol is an approved drug. It has reached clinical phase 4. It is classified as a Protein.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL5315071. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

Aviso Médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.